MedTrace Logo

Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

NCT03311984 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2017-10-17

No results posted yet for this study

Summary

Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin（LMWH）, many patients still develop life-threatening embolism. The purpose of this study is to evaluate the anti-Xa levels of different dosing regimens of LMWH in critically ill patients in China.

Conditions

  • Critically Ill
  • Anti-Xa

Interventions

DIAGNOSTIC_TEST

anti Xa level

monitoring the anti-Xa level according to LMWH emploing

Sponsors & Collaborators

  • Southeast University, China

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2018-03-30
Completion
2018-05-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03311984 on ClinicalTrials.gov